Tuberculosis 2013 : 2 Tuberculosis biomarkers discovery : developments , needs , and challenges
暂无分享,去创建一个
Alimuddin Zumla | Marco Schito | Markus Maeurer | S. Cole | Alimuddin Zumla | M. Schito | B. Andrade | R. Wallis | M. Maeurer | Peter Kim | Stewart Cole | D. Hanna | P. Kim | Robert S Wallis | Bruno B Andrade | Debra Hanna
[1] G. Kaplan,et al. Specific T cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis, Following BCG Vaccination of Newborns , 2010 .
[2] G. Kaplan,et al. A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. , 2008, The Journal of infectious diseases.
[3] H. Okamura,et al. Increased levels of circulating interleukin-18 in patients with advanced tuberculosis. , 2000, American journal of respiratory and critical care medicine.
[4] M. Gennaro,et al. Serological markers of pulmonary tuberculosis and of response to anti-tuberculosis treatment in a patient population in Guinea. , 2006, International journal of immunopathology and pharmacology.
[5] R. Gie,et al. Immune parameters as markers of tuberculosis extent of disease and early prediction of anti-tuberculosis chemotherapy response. , 2008, The Journal of infection.
[6] K. Floyd,et al. Rapid molecular TB diagnosis: evidence, policy-making and global implementation of Xpert®MTB/RIF Weyer, , 2013 .
[7] R. Gie,et al. Baseline sputum time to detection predicts month two culture conversion and relapse in non-HIV-infected patients. , 2010, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] R. Wallis,et al. Sustainable tuberculosis drug development. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] C. Immanuel,et al. Serial evaluation of serum neopterin in HIV seronegative patients treated for tuberculosis. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[10] V. Pascual,et al. Detectable Changes in The Blood Transcriptome Are Present after Two Weeks of Antituberculosis Therapy , 2012, PloS one.
[11] M. Levin,et al. Reconstitution of antimycobacterial immune responses in HIV-infected children receiving HAART , 2006, AIDS.
[12] J. Ellner,et al. Bactericidal Activity in Whole Blood as a Potential Surrogate Marker of Immunity after Vaccination against Tuberculosis , 2002, Clinical and Vaccine Immunology.
[13] R. Wallis,et al. Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis , 2010, Antimicrobial Agents and Chemotherapy.
[14] M. Levin,et al. Novel Human In Vitro System for Evaluating Antimycobacterial Vaccines , 2004, Infection and Immunity.
[15] M. Perkins,et al. Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. , 2012, The Journal of infectious diseases.
[16] O. Lantz,et al. Antimicrobial activity of mucosal-associated invariant T cells , 2010, Nature Immunology.
[17] R. Wallis,et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. , 2006, The Journal of infectious diseases.
[18] A. Adegnika,et al. Specific cytokine patterns of pulmonary tuberculosis in Central Africa. , 2011, Clinical immunology.
[19] Prescott G Woodruff,et al. Sarcoidosis blood transcriptome reflects lung inflammation and overlaps with tuberculosis. , 2011, American journal of respiratory and critical care medicine.
[20] M. Levin,et al. Evaluation of human antimycobacterial immunity using recombinant reporter mycobacteria. , 2000, The Journal of infectious diseases.
[21] Yuxin Dong,et al. Antigens of Mycobacterium tuberculosis Recognized by Antibodies during Incipient, Subclinical Tuberculosis , 2005, Clinical Diagnostic Laboratory Immunology.
[22] Marcela Henao-Tamayo,et al. T lymphocyte surface expression of exhaustion markers as biomarkers of the efficacy of chemotherapy for tuberculosis. , 2011, Tuberculosis.
[23] M. Herbster,et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.
[24] W. Boom,et al. Sputum Mycobacterium tuberculosis mRNA as a Marker of Bacteriologic Clearance in Response to Antituberculosis Therapy , 2009, Journal of Clinical Microbiology.
[25] M. Barer,et al. Resuscitation-promoting factors reveal an occult population of tubercle Bacilli in Sputum. , 2010, American journal of respiratory and critical care medicine.
[26] P. D. Hart,et al. BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life. , 1977, British medical journal.
[27] N. Maine,et al. Randomised controlled trial of single BCG, repeated BCG, or combined BCG and killed Mycobacterium leprae vaccine for prevention of leprosy and tuberculosis in Malawi , 1996, The Lancet.
[28] J. Poole,et al. Demonstration of increased anti-mycobacterial activity in peripheral blood monocytes after BCG vaccination in British school children. , 1988, Clinical and experimental immunology.
[29] R. Sorensen,et al. Case-control study of the efficacy of BCG immunization against pulmonary tuberculosis in young adults in Santiago, Chile. , 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[30] Nicole A. Kruh,et al. Proteomic analysis identifies highly antigenic proteins in exosomes from M. tuberculosis‐infected and culture filtrate protein‐treated macrophages , 2010, Proteomics.
[31] M. Jacobsen,et al. SOCS3 promotes interleukin-17 expression of human T cells. , 2012, Blood.
[32] Dirk Repsilber,et al. Biomarkers of Inflammation, Immunosuppression and Stress Are Revealed by Metabolomic Profiling of Tuberculosis Patients , 2012, PloS one.
[33] D. Sack,et al. Use of Antibodies in Lymphocyte Secretions for Detection of Subclinical Tuberculosis Infection in Asymptomatic Contacts , 2004, Clinical Diagnostic Laboratory Immunology.
[34] R. Hussain,et al. Dynamic Changes in Biomarker Profiles Associated with Clinical and Subclinical Tuberculosis in a High Transmission Setting: A Four‐Year Follow‐Up Study , 2009, Scandinavian journal of immunology.
[35] K. Higuchi,et al. Interferon‐γ responses after isoniazid chemotherapy for latent tuberculosis , 2008, Respirology.
[36] A. Gandhe,et al. Host biomarkers of clinical relevance in tuberculosis: review of gene and protein expression studies , 2012, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[37] G. Vanham,et al. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. , 1999, The Journal of infectious diseases.
[38] S. Niemann,et al. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis. , 2008, American journal of respiratory and critical care medicine.
[39] R. Adegbola,et al. 8. INTERFERON GAMMA ELISPOT AS A BIOMARKER OF TREATMENT EFFICACY IN LATENT TUBERCULOSIS INFECTION: A RANDOMIZED, BLINDED AND PLACEBO CONTROLLED CLINICAL TRIAL , 2012 .
[40] D. Alling,et al. The after-history of pulmonary tuberculosis. VI. The first fifteen years following diagnosis. , 1960, The American review of respiratory disease.
[41] K. Lai,et al. Elevated interleukin-2 receptor level in patients with active pulmonary tuberculosis and the changes following anti-tuberculosis chemotherapy. , 1995, The European respiratory journal.
[42] J. Ellner,et al. Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. , 2002, The Journal of infectious diseases.
[43] K. Higuchi,et al. Relationship between whole-blood interferon-gamma responses and the risk of active tuberculosis. , 2008, Tuberculosis.
[44] Olaf Tietje,et al. Volatile biomarkers of pulmonary tuberculosis in the breath. , 2007, Tuberculosis.
[45] J. Parner,et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[46] R. Diel,et al. Predictive value of interferon-γ release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. , 2012, Chest.
[47] M. Perkins,et al. Measurement of sputum Mycobacterium tuberculosis messenger RNA as a surrogate for response to chemotherapy. , 1999, American journal of respiratory and critical care medicine.
[48] Bouke C. de Jong,et al. Identification of Probable Early-Onset Biomarkers for Tuberculosis Disease Progression , 2011, PloS one.
[49] Robert J Wilkinson,et al. A single dose of vitamin D enhances immunity to mycobacteria. , 2007, American journal of respiratory and critical care medicine.
[50] D. Mitchison. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. , 1993, The American review of respiratory disease.
[51] M. Barreto,et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial , 2005, The Lancet.
[52] A. Matteelli,et al. Early tuberculosis treatment monitoring by Xpert® MTB/RIF , 2012, European Respiratory Journal.
[53] M. Perkins,et al. Induction of the antigen 85 complex of Mycobacterium tuberculosis in sputum: a determinant of outcome in pulmonary tuberculosis treatment. , 1998, The Journal of infectious diseases.
[54] A. Cooper,et al. Cell-mediated immune responses in tuberculosis. , 2009, Annual review of immunology.
[55] O. Burghuber,et al. Peripheral T Cell Cytokine Responses for Diagnosis of Active Tuberculosis , 2012, PloS one.
[56] T. Eguale,et al. Immune Responses to the Mycobacterium tuberculosis-Specific Antigen ESAT-6 Signal Subclinical Infection among Contacts of Tuberculosis Patients , 2002, Journal of Clinical Microbiology.
[57] S. Niemann,et al. Negative and positive predictive value of a whole-blood interferon-γ release assay for developing active tuberculosis: an update. , 2011, American journal of respiratory and critical care medicine.
[58] Alimuddin Zumla,et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice , 2010, The Lancet.
[59] C. Di Serio,et al. A Genome-Wide Identification Analysis of Small Regulatory RNAs in Mycobacterium tuberculosis by RNA-Seq and Conservation Analysis , 2012, PloS one.
[60] F. Demiröz,et al. sICAM-1 as a serum marker in the diagnosis and follow-up of treatment of pulmonary tuberculosis. , 2002, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[61] P. V. van Helden,et al. Molecular Bacterial Load Assay, a Culture-Free Biomarker for Rapid and Accurate Quantification of Sputum Mycobacterium tuberculosis Bacillary Load during Treatment , 2011, Journal of Clinical Microbiology.
[62] M. Perkins,et al. A multisite assessment of the quantitative capabilities of the Xpert MTB/RIF assay. , 2011, American journal of respiratory and critical care medicine.
[63] S. Chambers,et al. The scent of Mycobacterium tuberculosis. , 2008, Tuberculosis.
[64] M. Herbster,et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum , 2006, The Lancet.
[65] P. V. van Helden,et al. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy , 2006, Clinical and experimental immunology.
[66] Z. Toossi,et al. Augmentation of apoptosis and interferon-gamma production at sites of active Mycobacterium tuberculosis infection in human tuberculosis. , 2001, The Journal of infectious diseases.
[67] Dirk Repsilber,et al. Correction: Biomarkers of Inflammation, Immunosuppression and Stress with Active Disease Are Revealed by Metabolomic Profiling of Tuberculosis Patients , 2012, PLoS ONE.
[68] K. Dheda,et al. Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients , 2012, European Respiratory Journal.
[69] M. Perkins,et al. Predicting the outcome of therapy for pulmonary tuberculosis. , 2000, American journal of respiratory and critical care medicine.
[70] A. I. Imani Fooladi,et al. Comparison of smear microscopy, culture, and real-time PCR for quantitative detection of Mycobacterium tuberculosis in clinical respiratory specimens , 2013, Scandinavian journal of infectious diseases.
[71] C. Nacy,et al. Early bactericidal activity of new drug regimens for tuberculosis , 2013, The Lancet.
[72] John L. Johnson,et al. Anti-phospholipid antibody levels as biomarker for monitoring tuberculosis treatment response. , 2012, Tuberculosis.
[73] F Doucet-Populaire,et al. (18)F-FDG PET/CT in tuberculosis: an early non-invasive marker of therapeutic response. , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[74] M. Brennan,et al. Tuberculosis vaccines: a strategic blueprint for the next decade. , 2012, Tuberculosis.
[75] D. Follmann,et al. Linezolid for treatment of chronic extensively drug-resistant tuberculosis. , 2012, The New England journal of medicine.
[76] Qian Gao,et al. Comparative miRNA Expression Profiles in Individuals with Latent and Active Tuberculosis , 2011, PloS one.
[77] G. Besra,et al. Biogenesis of the mycobacterial cell wall and the site of action of ethambutol , 1995, Antimicrobial agents and chemotherapy.
[78] J. Ellner,et al. A whole blood bactericidal assay for tuberculosis. , 2001, The Journal of infectious diseases.
[79] Alimuddin Zumla,et al. Immunological biomarkers of tuberculosis , 2011, Nature Reviews Immunology.
[80] B. Vickery,et al. An Interferon-Inducible Neutrophil-Driven Blood Transcriptional Signature in Human Tuberculosis , 2011, Pediatrics.
[81] C. F. von Reyn,et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[82] T. Clark,et al. Distinct phases of blood gene expression pattern through tuberculosis treatment reflect modulation of the humoral immune response. , 2013, The Journal of infectious diseases.
[83] W. Boom,et al. Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures. , 2011, Tuberculosis.
[84] John L. Johnson,et al. CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. , 2011, American journal of respiratory and critical care medicine.
[85] Ho-Yeon Song,et al. Lack of Activity of Orally Administered Clofazimine against Intracellular Mycobacterium tuberculosis in Whole-Blood Culture , 2004, Antimicrobial Agents and Chemotherapy.
[86] R. Wallis,et al. Strain specificity of antimycobacterial immunity in whole blood culture after cure of tuberculosis. , 2009, Tuberculosis.
[87] M. Amicosante,et al. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[88] G. Pantaleo,et al. Dominant TNF-α+ Mycobacterium tuberculosis–specific CD4+ T cell responses discriminate between latent infection and active disease , 2011, Nature Medicine.
[89] G. Ippolito,et al. Mycobacterium tuberculosis DNA detection in soluble fraction of urine from pulmonary tuberculosis patients. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[90] C. Laymon,et al. Infection Dynamics and Response to Chemotherapy in a Rabbit Model of Tuberculosis using [18F]2-Fluoro-Deoxy-d-Glucose Positron Emission Tomography and Computed Tomography , 2012, Antimicrobial Agents and Chemotherapy.
[91] Kenneth G. C. Smith,et al. Dendritic Cell Stimulation by Mycobacterial Hsp70 Is Mediated Through CCR5 , 2006, Science.
[92] J. Achkar,et al. Incipient and subclinical tuberculosis: defining early disease states in the context of host immune response. , 2011, The Journal of infectious diseases.
[93] N. Garrett,et al. Latent and subclinical tuberculosis in HIV infected patients: a cross-sectional study , 2012, BMC Infectious Diseases.
[94] D. Fuchs,et al. Neopterin, β2-Microglobulin, and Acute Phase Proteins in HIV-1-Seropositive and -Seronegative Zambian Patients with Tuberculosis , 1997, Lung.
[95] Paul D van Helden,et al. Gene-expression patterns in whole blood identify subjects at risk for recurrent tuberculosis. , 2007, The Journal of infectious diseases.
[96] Aaron S. Anderson,et al. Rapid detection of Mycobacterium tuberculosis biomarkers in a sandwich immunoassay format using a waveguide-based optical biosensor. , 2012, Tuberculosis.
[97] J. Ellner,et al. Subclinical tuberculosis: a new entity? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[98] John L. Johnson,et al. Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment Trials , 2010, Journal of Clinical Microbiology.
[99] John L. Johnson,et al. Inhibition of Isoniazid-Induced Expression of Mycobacterium tuberculosis Antigen 85 in Sputum: Potential Surrogate Marker in Tuberculosis Chemotherapy Trials , 2001, Antimicrobial Agents and Chemotherapy.
[100] L. Aarons,et al. Use of Nonlinear Mixed-Effects Analysis for Improved Precision of Early Pharmacodynamic Measures in Tuberculosis Treatment , 2006, Antimicrobial Agents and Chemotherapy.
[101] D. DeMets,et al. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.
[102] Alling Dw,et al. The after-history of pulmonary tuberculosis. IV. Far advanced tuberculosis. , 1954 .
[103] A. Diacon,et al. Early Bactericidal Activity and Pharmacokinetics of the Diarylquinoline TMC207 in Treatment of Pulmonary Tuberculosis , 2008, Antimicrobial Agents and Chemotherapy.
[104] B. Eley,et al. Failure to control growth of mycobacteria in blood from children infected with human immunodeficiency virus and its relationship to T cell function. , 2003, The Journal of infectious diseases.
[105] R. Balderas,et al. Corrigendum: Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.
[106] R. Balderas,et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction , 2006, Nature Medicine.
[107] M. Pai,et al. Predictive value of interferon-γ release assays for incident active tuberculosis: a systematic review and meta-analysis. , 2012, The Lancet. Infectious diseases.
[108] S. Lawn,et al. Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria , 2012, BMC Infectious Diseases.
[109] K. Dheda,et al. The Diagnostic Accuracy of Urine-Based Xpert MTB/RIF in HIV-Infected Hospitalized Patients Who Are Smear-Negative or Sputum Scarce , 2012, PloS one.
[110] Alimuddin Zumla,et al. Biomarkers for tuberculosis disease activity, cure, and relapse. , 2009, The Lancet. Infectious diseases.
[111] R. Diel,et al. Interferon-&ggr; release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis , 2010, European Respiratory Journal.
[112] S. Lawn,et al. Serum C-reactive protein and detection of tuberculosis in persons co-infected with the human immunodeficiency virus. , 2001, Transactions of the Royal Society of Tropical Medicine and Hygiene.
[113] D. Mitchison,et al. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis , 2001, BMC pulmonary medicine.
[114] John L. Johnson,et al. Sputum Cytokine Levels in Patients with Pulmonary Tuberculosis as Early Markers of Mycobacterial Clearance , 2002, Clinical and Vaccine Immunology.
[115] M. Barreto,et al. BCG Revaccination Does Not Protect Against Leprosy in the Brazilian Amazon: A Cluster Randomised Trial , 2008, PLoS neglected tropical diseases.
[116] D Repsilber,et al. Human gene expression profiles of susceptibility and resistance in tuberculosis , 2011, Genes and Immunity.
[117] Alimuddin Zumla,et al. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test. , 2013, The Lancet. Infectious diseases.
[118] Matthew S. Cook,et al. Human Mucosal Associated Invariant T Cells Detect Bacterially Infected Cells , 2010, PLoS biology.
[119] John L. Johnson,et al. Whole blood bactericidal activity during treatment of pulmonary tuberculosis. , 2003, The Journal of infectious diseases.
[120] M. Chan-yeung,et al. Efficacy of the BCG revaccination programme in a cohort given BCG vaccination at birth in Hong Kong. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[121] John L. Johnson,et al. Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. , 2008, American journal of respiratory and critical care medicine.
[122] P. V. van Helden,et al. Changes in leucocyte and lymphocyte subsets during tuberculosis treatment; prominence of CD3dimCD56+ natural killer T cells in fast treatment responders , 2006, Clinical and experimental immunology.
[123] W. Rom,et al. Time to detection of Mycobacterium tuberculosis in sputum culture correlates with outcome in patients receiving treatment for pulmonary tuberculosis. , 1998, Chest.
[124] G. Kaplan,et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. , 2010, American journal of respiratory and critical care medicine.
[125] G. Scott,et al. Predicting deterioration of treated tuberculosis by corticosteroid reserve and C-reactive protein. , 1990, The Journal of infection.
[126] A. Rattan,et al. Prognostic value of 'C' reactive protein in tuberculosis. , 1989, Indian pediatrics.
[127] M. Perkins,et al. Detection of Viable Mycobacterium tuberculosis by Reverse Transcriptase-Strand Displacement Amplification of mRNA. , 1999, Methods in molecular medicine.
[128] Boping Zhou,et al. Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions , 2012, PLoS pathogens.